Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 174 results
October 2019
-
Media ReleaseNovartis receives approval for Cosentyx® label update in Europe to include dosing flexibility in ankylosing spondylitisNew Cosentyx® (secukinumab) label to include 300 mg up-titration option is informed by results from the Phase III MEASURE 3 study[1] Approval provides clinicians with greater choice for their…
-
Media ReleaseNovartis data show Cosentyx® treatment results in rapid and sustained resolution of signs and symptoms of psoriatic arthritis in patients with and without enthesitisNew two-year data compare the effects of Cosentyx (secukinumab) treatment in psoriatic arthritis patients with and without enthesitis, a manifestation described in 30-50% of patients [1] Results…
-
Media ReleaseNovartis data show more patients are completely symptom-free from chronic spontaneous urticaria with ligelizumab (QGE031) than Xolair® 300 mgResults from a Phase IIb dose-finding study show an average complete response rate of 42% for doses 240 mg and 72 mg ligelizumab at Week 12 compared with 26% for those taking 300 mg Xolair’s dose (…
June 2019
-
Media ReleaseNovartis highlights new publication showing IL-17A antibody Cosentyx® improves inflammation and rapidly suppresses IL-23 in plaque psoriasisNew data show that Cosentyx modulates gene expression leading to substantial improvement of inflammation, as early as Week 12 by reversing plaque histopathology in the majority of patients[1]…
-
Media ReleaseNovartis provides update on phase 2b ENCORE-LF trial in NASH cirrhosisConatus today announced top-line results from the ENCORE-LF trial, which did not meet its primary endpoint Novartis remains fully committed to pursuing the development of multiple compounds in…
-
Media ReleaseNew Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacyData show switching to Hyrimoz® (biosimilar adalimumab) from the reference medicine provides sustained efficacy with no new safety concerns in patients with moderate-to-severe rheumatoid arthritis[…
-
Media ReleaseThree quarters of people living with axial spondyloarthritis struggle to find a job, IMAS survey showsNew European data from IMAS survey show that people living with axial spondyloarthritis (axSpA) suffer a delay in diagnosis of over 7 years, potentially leading to an increase in work-related…
-
Media ReleaseCosentyx® provides long-lasting inhibition of radiographic progression in psoriatic arthritis, new Novartis data showAlmost 90% of patients had no radiographic progression of psoriatic arthritis (PsA) at 2 years with Cosentyx (secukinumab) 300mg[1] Data at 2 years demonstrate over 50% of adults with…
-
Media ReleaseNovartis presents first-of-its-kind histology data with iscalimab (CFZ533) suggesting the extended survival of transplanted organs may be possibleData show 60% of iscalimab-treated transplant patients have normal kidney histology at least 1 year after transplant vs 0% with tacrolimus (current standard of care)[1] Less than half of donated…
Pagination
- ‹ Previous page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- …
- 15
- › Next page